MIMS Education
Human Milk Oligosaccharides: Multi-faceted Defense Against Infections & Inflammation
Cat 3A: 1 Point | 
2h | 
28 Apr 2020
Overview
About this course
Human milk oligosaccharides (HMOs) in breast milk provide immune-nourishing benefits to babies. Infant formula formulated with 2'-fucosyllactose (2'-FL) HMO, which is structurally identical to the HMOs found in breast milk, may help close the health gap between breastfed and formula-fed babies. This lecture discusses the role of HMOs in paediatric gut health and immunity, with emphasis on 2'-FL.
Who should attend
Pediatricians, Obstetricians and Gynecologists, General Practitioners and Dietitians and Pharmacists
1 CME Point Available (Category 3A)
- Complete the videos and quiz to qualify for 1 CME Point (Category 3A).
- Not accredited for Dietitians and Pharmacists.
- A certificate will be provided upon successful completion. Please use the information on the certificate to claim your points via SMC website.
- Doctors who have attended the face-to-face meeting will not be eligible for additional CME points for completing this module.
Organized under the auspices of:
Supported by an educational grant from
Our Speakers
HMOs in Breast Milk: Understanding Concentration, Composition and Variation
Associate Prof Anne Goh is Head of the Allergy Service at KK Women’s and Children’s Hospital and a senior consultant with the Respiratory Medicine Service. She did her training in Respirology in the Hospital for Sick Children, Toronto, Canada under Dr Hugh O’Brodovitch. Her sub-specialty interests include asthma and allergic diseases, neuromuscular diseases and its lung complications, paediatric interstitial lung diseases, respiratory infections, and sleep disordered breathing. She is a recipient of many awards, including the Excellent Service Award (gold and star in 2003 and 2004, respectively), and has published many papers.
HMOs in Clinical Practice: Influence on Gut Health, Systemic Immunity and More
Dr Mark Underwood is Professor of Paediatrics and Chief, Division of Neonatology at the University of California Davis, Sacramento, California, US. His research focuses predominantly on the serious intestinal disease necrotizing enterocolitis. He conducts cohort studies and clinical trials of probiotic bifidobacteria and prebiotic oligosaccharides in premature and term infants, and other infant populations. He has provided paediatric care in Peru, Vietnam, Bangladesh, Brazil, and St. Lucia and taught neonatal resuscitation courses to physicians, nurses, and birth attendants in Lesotho, Botswana, Nigeria, Egypt, Lebanon, Kazahkstan, Kyrgyzstan, Tajikistan, Uzbekistan, Ukraine, Romania, Bosnia and Serbia.